Cue Biopharma, Inc. (CUE)

Market Cap	94.67M +109.0%
Revenue (ttm)	32.73M +309.6%
Net Income	-19.52M
EPS	-5.22
Shares Out	3.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,328
Open	28.99
Previous Close	29.46
Day's Range	27.53 - 32.60
52-Week Range	4.97 - 41.42
Beta	2.55
Analysts	n/a
Price Target	n/a
Earnings Date	May 14, 2026

About CUE

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 2, 2018
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: CUE
• Website: https://www.cuebiopharma.com

Financial Performance

In 2025, Cue Biopharma's revenue was $27.47 million, an increase of 195.75% compared to the previous year's $9.29 million. Losses were -$26.60 million, -34.60% less than in 2024.